Predictive Factors of Fetal Cardiac Manifestations of Neonatal Lupus in Anti-SSA/Ro and/or SSB/La Antibody-Positive Pregnant Women
American Journal of Perinatology · 01.04.2026 · 43 (05) · 571-578
DOI: 10.1055/a-2657-6178 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.04.2026. Verfasst von Jian Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Maternal-Fetal Medicine Center in Fetal Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Antibodies, Antinuclear, Pregnancy Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Beijing Natural Science Foundation, Beijing Key Laboratory of Maternal-Fetal Medicine in Fetal Heart Disease, Beijing Municipal Commission of Science and Technology.
Abstract (Originalsprache)
The factors associated with the development of cardiac manifestations of neonatal lupus (cardiac-NL) in fetuses with positive anti-SSA/Ro and/or SSB/La (anti-SSA/SSB) antibodies are unclear. This study aimed to investigate the predictive factors of fetal cardiac-NL in anti-SSA/SSB antibody-positive pregnant women. A total of 669 pregnant women with positive anti-SSA/SSB antibodies were retrospectively included. We determined whether the fetus had cardiac-NL and collected relevant clinical data. Univariate and multivariate analyses were performed to analyze the correlation between fetal cardiac-NL and clinical characteristics. Among 669 pregnant women with positive anti-SSA/SSB antibody tests, 26 cases of fetal cardiac-NL occurred. Univariate analysis showed that fetal cardiac-NL was positively correlated with the assisted reproduction (odds ratio [OR]: 2.824; p = 0.045), strong positive anti-SSA/SSB antibody (OR: 6.437; p < 0.001), and clinical diagnosis of connective tissue disease (CTD; OR: 4.701; p = 0.037); it was negatively correlated with the use of hydroxychloroquine (HCQ; OR: 0.187; p < 0.001) and aspirin (OR: 0.369; p = 0.048). Multivariate analysis showed that the assisted reproduction (OR: 4.110; p = 0.029), strong positive anti-SSA/SSB antibody (OR: 8.691; p < 0.001), and clinical diagnosis of CTD (OR: 8.614; p = 0.010) were risk factors for fetal cardiac-NL; while HCQ (OR: 0.091; p < 0.001) and aspirin (OR: 0.318; p = 0.035) were protective factors for fetal cardiac-NL. This study determined that assisted reproduction, strong positive anti-SSA/SSB antibody, and clinical diagnosis of CTD are independent risk factors for fetal cardiac-NL. The use of HCQ and aspirin are independent protective factor for fetal cardiac-NL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Maternal-Fetal Medicine Center in Fetal Heart Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Jian Wu
Förderung
- Beijing Natural Science Foundation
- Beijing Key Laboratory of Maternal-Fetal Medicine in Fetal Heart Disease
- Beijing Municipal Commission of Science and Technology
- Beijing Key Laboratory of Maternal–Fetal Medicine in Fetal Heart Disease
Zitieren
APA
Wu, J., Ruan, Y., Wang, H., Gu, X., Han, J., & He, Y. (2026). Predictive Factors of Fetal Cardiac Manifestations of Neonatal Lupus in Anti-SSA/Ro and/or SSB/La Antibody-Positive Pregnant Women. American Journal of Perinatology, 43(05), 571-578. https://doi.org/10.1055/a-2657-6178
Vancouver
Wu J, Ruan Y, Wang H, Gu X, Han J, He Y. Predictive Factors of Fetal Cardiac Manifestations of Neonatal Lupus in Anti-SSA/Ro and/or SSB/La Antibody-Positive Pregnant Women. American Journal of Perinatology. 2026;43(05):571-578. doi:10.1055/a-2657-6178
BibTeX
@article{Wu2026,
author = {Wu, Jian and Ruan, Yanping and Wang, Hairui and Gu, Xiaoyan and Han, Jiancheng and He, Yihua},
title = {Predictive Factors of Fetal Cardiac Manifestations of Neonatal Lupus in Anti-SSA/Ro and/or SSB/La Antibody-Positive Pregnant Women},
journal = {American Journal of Perinatology},
year = {2026},
volume = {43},
number = {05},
pages = {571--578},
doi = {10.1055/a-2657-6178}
}
EUVIMED